Immuneering IMRX September 2024 Investor Presentation

Immuneering Corporation (IMRX) presents its universal-RAS/RAF franchise focused on developing uniquely designed MEK inhibitors. The presentation highlights Phase 1 results for lead candidate IMM-1-104, which demonstrated excellent tolerability and activity in pancreatic cancer, with Phase 2a trials underway for combination therapies addressing an estimated 200,000+ patients with RAS or RAF-driven tumors.